Apimeds Pharmaceuticals US, Inc
The global leader in the therapeutic application of purified Apis mellifera (honey bee) venom for inflammatory conditions
Ready to Maximize the Apitox Opportunity
US company established in
May 2020
Based in Matawan, NJ
Subsidiary of Inscobee Inc
Form S-1 filed with the SEC on September 25, 2024
Primary asset is Apitox, licensed from Apimeds Korea
Initially being developed as a potential treatment for pain and inflammation in patients with knee osteoarthritis
Apitox has a demonstrated track record of real-world usage and experience, with facilities in South Korea administering Apitox commercially since 2003
~330 patients were treated in a previously conducted Phase 3 knee osteoarthritis trial, which demonstrated clinical efficacy and safety of Apitox in a US population
A follow-up FDA meeting in 2018 confirmed the need for a second confirmatory Phase 3 trial
Apimeds works in concert with national support societies to provide patients with the broadest range of information and updates. Please see below to research more about Osteoarthritis and/or Multiple Sclerosis.
Arthritis Foundation
1355 Peachtree St NE Suite 600
Atlanta, GA 30309
National Multiple Sclerosis Society
733 Third Avenue 3rd Floor New York, NY 10017 USA
Corporate
Presentation
Get in Touch
Feel free to reach out by phone, email, or through our online contact form. We’re here to help and look forward to connecting with you.
Address
Apimeds Pharmaceuticals US, Inc. 25 Edinburg Circle Matawan, NJ 07747
